
Keywords: Breast cancer; HER-2-negative; Resistance; Biologic targeted agent; Combination therapy; ABC; advanced breast cancer; AE; adverse event; AI; aromatase inhibitor; AKT; protein kinase; BC; breast cancer; CDK; cyclin-dependent kinase; CT; chemotherapy; CTLA;